Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Izalontamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Izalontamab overview

SIB-001 is under development for the treatment of squamous non-small cell lung carcinoma, squamous non-small cell lung cancer, epithelium squamous cell carcinomas including advanced or metastatic epithelial tumors including esophageal squamous cell carcinoma, lung squamous cell carcinoma, non-small cell lung cancer triple negative breast cancer, nasopharyngeal cancer, colon cancer, lung adenocarcinoma head and neck squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer. The drug candidate is a dual blockade bi-specific antibody. It is developed based on specificity enhanced bi-specific antibody (SEBA) platform. It is administered through intravenous route. It acts by targeting both EGFR and HER3.

It was also under development for the treatment of metastatic colorectal cancer and gastric cancer.

Systimmune overview

Systimmune, a subsidiary of Sichuan Biokin Pharmaceutical Co Ltd, is a biopharmaceutical company. It utilizes specificity-enhanced bi-specific antibody (SEBA), guidance and navigation control (GNC) and HIRE-ADC platforms to develop novel therapeutic bi-specific, multi-specific antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. The company’s pipeline products include SI-B001, SI-B003, BL-B01D1, BL-M07D1 and BL-M02D1 target solid tumors; GNC-038, GNC-035 and GNC-039 treats lymphoma, leukemia, solid tumors and glioblastoma; and BL-M11D1 and BL-M05D1 are monospecific antibodies for R/R AML (acute myeloid leukemia) and gastric cancer. Systimmune is headquartered in Redmond, Washington, the US.

For a complete picture of Izalontamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.